Pharmaceutical News

RSS

Prescription painkiller abuse: A worst drug overdose epidemic in history

The Centers for Disease Control calls prescription painkiller abuse "one of the worst drug overdose epidemics in history."

19 Feb 2015

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens.

19 Feb 2015

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute.

19 Feb 2015

EC grants orphan drug designation to aTyr Pharma's Resolaris for treatment of FSHD

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today the European Commission (EC) has granted orphan drug designation to Resolaris for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

19 Feb 2015

Midwest Compassion Center, Dr. Alan Shackelford join forces to treat epilepsy through medical cannabis

Midwest Compassion Center and Dr. Alan Shackelford join forces in the fight to treat epilepsy through the use of medical cannabis at their Will County dispensary. With growing concerns over the potentially negative side effects of pharmaceuticals and their inability to provide adequate symptom control in as many as 30% of patients with seizures, Dr. Shackelford and MCC will collaborate on research with the goal of developing new treatment options for patients dealing with a debilitating illness or condition, including seizures.

19 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees.

18 Feb 2015

Nicotine addiction medication produces greater reductions in smoking prior to quitting

Among cigarette smokers not willing or able to quit smoking in the next month but willing to reduce with the goal of quitting in the next 3 months, use of the nicotine addiction medication varenicline for 24 weeks compared with placebo produced greater reductions in smoking prior to quitting and increased smoking cessation rates at the end of treatment and at 1 year, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Among patients with severe community-acquired pneumonia and high initial inflammatory response, the use of the corticosteroid methylprednisolone decreased treatment failure, compared with placebo, according to a study in the February 17 issue of JAMA.

18 Feb 2015

Rivers, streams could be a major source of antibiotic resistance in the environment

Rivers and streams could be a major source of antibiotic resistance in the environment. The discovery comes following a study on the Thames river by scientists at the University of Warwick's School of Life Sciences and the University of Exeter Medical School.

17 Feb 2015

Cabazitaxel therapy may be more effective in treating prostate cancer

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.

17 Feb 2015

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

17 Feb 2015

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced today that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus®.

17 Feb 2015

BGRF announces publication of research into personalising nootropic drugs using in silico prediction methods

The Biogerontology Research Foundation (BGRF), a UK-based charity committed to the support of aging research to address the challenges of a rapidly aging population and to reduce the impact of disease on future generations, announces the publication of research into personalising nootropic drugs using in silico prediction methods.

17 Feb 2015

Experts provide suggestions to prevent neurological injuries associated with epidural steroid injections

Epidural steroid injections are commonly used to treat pain; however, they can in rare situations produce life-threatening neurological injuries such as stroke and paralysis. In the Online First edition of February's Anesthesiology, the official medical journal of the American Society of Anesthesiologists, a panel of experts representing 13 national medical organizations provided 17 suggestions aimed at preventing such injuries and improving patient safety.

16 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

AARDA releases white paper to educate its members, patient community about biosimilar medicines

The American Autoimmune Related Diseases Association, a national nonprofit health organization dedicated to increasing awareness of autoimmune diseases, today issued a white paper to educate its membership and the patient community about biosimilar medicines after a survey found most patients were generally unaware of this new category of medicines which may soon be approved in the U.S.

16 Feb 2015

Increasing opioid doses to manage chronic pain may intensify depression

Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to Saint Louis University findings in Pain.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

While debate about recreational marijuana use continues, researchers are investigating the effectiveness of cannabis for treating pain, spasticity, and a host of other medical problems. In a symposium organized by the McGill University Health Centre as part of the 2015 American Association for the Advancement of Science Annual Meeting held this week in San Jose, California, world-renowned experts from North America and the U.K. share their perspectives on the therapeutic potential of medical cannabis and explore the emerging science behind it.

16 Feb 2015

Pharmaceutical News

Prescription painkiller abuse: A worst drug overdose epidemic in history

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

Ranibizumab drug reverses diabetes-related blindness

EC grants orphan drug designation to aTyr Pharma's Resolaris for treatment of FSHD

Midwest Compassion Center, Dr. Alan Shackelford join forces to treat epilepsy through medical cannabis

Actavis provides overview of standalone global pharmaceutical development pipeline

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Nicotine addiction medication produces greater reductions in smoking prior to quitting

Corticosteroids decrease treatment failure among patients with community-acquired pneumonia

Rivers, streams could be a major source of antibiotic resistance in the environment

Cabazitaxel therapy may be more effective in treating prostate cancer

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

BGRF announces publication of research into personalising nootropic drugs using in silico prediction methods

Experts provide suggestions to prevent neurological injuries associated with epidural steroid injections

Hospira announces launch of first biosimilar monoclonal antibody in Europe

AARDA releases white paper to educate its members, patient community about biosimilar medicines

Increasing opioid doses to manage chronic pain may intensify depression

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News